Ionis Pharmaceuticals Inc Q3 2023 Earnings Call Summary - Thomson StreetEvents

Ionis Pharmaceuticals Inc Q3 2023 Earnings Call Summary

Ionis Pharmaceuticals Inc Q3 2023 Earnings Call Summary - Thomson StreetEvents
Ionis Pharmaceuticals Inc Q3 2023 Earnings Call Summary
Published Nov 02, 2023
17 pages (10004 words) — Published Nov 02, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of IONS.OQ earnings conference call or presentation 2-Nov-23 3:30pm GMT

  
Brief Excerpt:

...A. We are on the cusp of delivering our near-term commercial medicines to patients starting with the first potential approval of eplontersen this year. B. We and our co-commercialization partner, AstraZeneca, are prepared to launch eplontersen following U.S. approval. C. We recently achieved another of our key objectives for eplontersen with the publication of a comprehensive review of the Phase III NEURO-TTRansform study results in JAMA. D. Based on its strong overall profile, including highly positive Phase III data, together with the freedom of a simple at-home monthly self-administration profile, we believe eplontersen is well positioned to become the therapy of choice for ATTR patients who remain underserved by current therapies. E. We were very pleased with the positive top line data we reported last month from our olezarsen Phase III BALANCE study in patients with FCS. F. Olazarsen showed significant triglyceride reductions, which was the studies primary efficacy end point along...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Ionis Pharmaceuticals Inc
Ticker
IONS.OQ
Time
3:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Can you remind me of your expectations around whether in addition to a clear impact on triglycerides whether you believe you could show an impact on pancreatitis for olezarsen in SHTG. And then second, forgive me if you stated this, but for CARDIO-TTRansform, I believe the ball is up to 140 weeks. I just wanted to clarify, is there a minimum planned follow-up for those who do not reach 140 weeks I noticed some of the endpoints are assessed a week, I think, 121. Is that the minimum assuming the study has not stopped early?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : And then in the event you don't stop the study early, what the minimum would be?

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : I just had a question on ION904. I think you've got an upcoming presentation at American Heart Association. Just wondering whether we should be thinking about similar AGT knockdown to the previous like a molecule and just more infrequent dosing or is that potential to get more than that sort of 75% that we're seeing with that molecule?

Table Of Contents

Ionis Pharmaceuticals Inc at Stifel Healthcare Conference Summary – 2023-11-14 – US$ 54.00 – Edited Brief of IONS.OQ presentation 14-Nov-23 3:55pm GMT

Ionis Pharmaceuticals Inc at Stifel Healthcare Conference Transcript – 2023-11-14 – US$ 54.00 – Edited Transcript of IONS.OQ presentation 14-Nov-23 3:55pm GMT

Ionis Pharmaceuticals Inc at Guggenheim Securities Inflammation & Immunology Conference Summary – 2023-11-07 – US$ 54.00 – Edited Brief of IONS.OQ presentation 7-Nov-23 4:10pm GMT

Ionis Pharmaceuticals Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript – 2023-11-07 – US$ 54.00 – Edited Transcript of IONS.OQ presentation 7-Nov-23 4:10pm GMT

Ionis Pharmaceuticals Inc Q3 2023 Earnings Call Transcript – 2023-11-02 – US$ 54.00 – Edited Transcript of IONS.OQ earnings conference call or presentation 2-Nov-23 3:30pm GMT

Ionis Pharmaceuticals Inc to discuss Olezarsen Top Line Phase 3 results. Summary – 2023-09-26 – US$ 54.00 – Edited Brief of IONS.OQ conference call or presentation 26-Sep-23 3:00pm GMT

Ionis Pharmaceuticals Inc to discuss Olezarsen Top Line Phase 3 results. Transcript – 2023-09-26 – US$ 54.00 – Edited Transcript of IONS.OQ conference call or presentation 26-Sep-23 3:00pm GMT

Ionis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Summary – 2023-09-12 – US$ 54.00 – Edited Brief of IONS.OQ presentation 12-Sep-23 4:15pm GMT

Ionis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-12 – US$ 54.00 – Edited Transcript of IONS.OQ presentation 12-Sep-23 4:15pm GMT

Ionis Pharmaceuticals Inc at Citi BioPharma Conference Transcript – 2023-09-07 – US$ 54.00 – Edited Transcript of IONS.OQ presentation 7-Sep-23 5:50pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Ionis Pharmaceuticals Inc Q3 2023 Earnings Call Summary" Nov 02, 2023. Alacra Store. May 17, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2023-Ionis-Pharmaceuticals-Inc-Earnings-Call-B15777461>
  
APA:
Thomson StreetEvents. (2023). Ionis Pharmaceuticals Inc Q3 2023 Earnings Call Summary Nov 02, 2023. New York, NY: Alacra Store. Retrieved May 17, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2023-Ionis-Pharmaceuticals-Inc-Earnings-Call-B15777461>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.